Scott Christopher K.
Known title: COO, CFO & SecretaryCIK: 0001613803
Associated companies
Transaction History
| IRMD | ▼ Sell | Open Market | 19,286 | $965K | 2/11/2022 | View on chart |
| IRMD | ▲ Buy | Option Exercise | 1,575 | — | 12/7/2021 | View on chart |
| IRMD | ▼ Sell | Tax Withholding | 620 | $30K | 12/7/2021 | View on chart |
| IRMD | ▲ Buy | Option Exercise | 2,732 | — | 12/7/2021 | View on chart |
| IRMD | ▼ Sell | Tax Withholding | 1,076 | $52K | 12/7/2021 | View on chart |
| IRMD | ▲ Buy | Option Exercise | 2,952 | — | 12/4/2021 | View on chart |
| IRMD | ▼ Sell | Tax Withholding | 1,162 | $52K | 12/4/2021 | View on chart |
| IRMD | ▲ Buy | Grant | 26,715 | $263K | 11/23/2021 | View on chart |
| IRMD | ▼ Sell | Open Market | 26,715 | $1.1M | 11/23/2021 | View on chart |
| IRMD | ▲ Buy | Grant | 2,003 | $20K | 11/17/2021 | View on chart |
| IRMD | ▼ Sell | Open Market | 2,003 | $80K | 11/17/2021 | View on chart |
| IRMD | ▼ Sell | Open Market | 4,255 | $170K | 11/16/2021 | View on chart |
| IRMD | ▲ Buy | Grant | 4,255 | $42K | 11/16/2021 | View on chart |
| IRMD | ▲ Buy | Grant | 2,027 | $20K | 11/15/2021 | View on chart |
| IRMD | ▼ Sell | Open Market | 2,027 | $81K | 11/15/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
iRadimed Gets Needham Hold Rating and Conference Participation
Needham initiated coverage on iRadimed with a Hold rating, while the company announced it will speak at the ROTH Healthcare Opportunities Conference. These developments add analyst visibility to the stock, which is currently trading near its 52-week high. The new coverage provides a fresh perspective on the company's position in the medical imaging sector.
iRadimed Gets Needham Hold Rating and Conference Participation. Needham initiated coverage on iRadimed with a Hold rating, while the company announced it will speak at the ROTH Healthcare Opportunities Conference. These developments add analyst visibility to the stock, which is currently trading near its 52-week high. The new coverage provides a fresh perspective on the company's position in the medical imaging sector.